Literature DB >> 9536492

MRIW: parametric analysis software for contrast-enhanced dynamic MR imaging in cancer.

G J Parker1, J Suckling, S F Tanner, A R Padhani, J E Husband, M O Leach.   

Abstract

A software package called the Magnetic Resonance Imaging Workbench has been developed to characterize contrast agent uptake in vivo following T1-weighted magnetic resonance (MR) imaging with qualitative analysis of changes in signal intensity or quantitative analysis of changes in contrast agent concentration over time. Various descriptors may be calculated from the analysis of dynamic contrast agent-enhanced MR studies and visualized as false-color overlays, which allow the immediate display and interpretation of information taken from a series of images acquired over time. Qualitative descriptors include onset of enhancement, initial gradient, mean gradient, maximum enhancement, and washout. These parameters can be particularly useful in the investigation of multifocal or widespread disease. Quantitative descriptors include capillary permeability-surface area product, extracellular volume, and T1 and may be used to monitor changes in the disease state and to assess the efficacy of treatment. In addition, they allow comparison of data obtained from different patients, from independent MR studies, or from studies performed with different modalities. Analysis of contrast enhancement during MR imaging in terms of such qualitative or quantitative parameters is a promising new method of data analysis in radiology.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9536492     DOI: 10.1148/radiographics.18.2.9536492

Source DB:  PubMed          Journal:  Radiographics        ISSN: 0271-5333            Impact factor:   5.333


  6 in total

1.  Magnetic Resonance Imaging for Drug Development.

Authors:  Jeong Kon Kim
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 2.  Application of magnetic resonance imaging to angiogenesis in breast cancer.

Authors:  M O Leach
Journal:  Breast Cancer Res       Date:  2001       Impact factor: 6.466

3.  The assessment of antiangiogenic and antivascular therapies in early-stage clinical trials using magnetic resonance imaging: issues and recommendations.

Authors:  M O Leach; K M Brindle; J L Evelhoch; J R Griffiths; M R Horsman; A Jackson; G C Jayson; I R Judson; M V Knopp; R J Maxwell; D McIntyre; A R Padhani; P Price; R Rathbone; G J Rustin; P S Tofts; G M Tozer; W Vennart; J C Waterton; S R Williams; P Workman
Journal:  Br J Cancer       Date:  2005-05-09       Impact factor: 7.640

4.  Effects of platinum/taxane based chemotherapy on acute perfusion in human pelvic tumours measured by dynamic MRI.

Authors:  K J Lankester; N J Taylor; J J Stirling; J Boxall; J A D'Arcy; M O Leach; G J S Rustin; A R Padhani
Journal:  Br J Cancer       Date:  2005-10-31       Impact factor: 7.640

5.  The use of error-category mapping in pharmacokinetic model analysis of dynamic contrast-enhanced MRI data.

Authors:  Andrew B Gill; Gayathri Anandappa; Andrew J Patterson; Andrew N Priest; Martin J Graves; Tobias Janowitz; Duncan I Jodrell; Tim Eisen; David J Lomas
Journal:  Magn Reson Imaging       Date:  2014-11-07       Impact factor: 2.546

6.  Dynamic contrast-enhanced MR imaging.

Authors:  A R Padhani
Journal:  Cancer Imaging       Date:  2000-10-11       Impact factor: 3.909

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.